BioSpace News Archive

Gritstone bio, Inc. announced that the company’s Board of Directors has granted eight employees nonqualified stock options to purchase an aggregate of 67,550 shares of its common stock with an exercise price of $2.66, which is equal to the closing price of Gritstone’s common stock on June 23, 2022, the grant date of the awards.

Astria Therapeutics, Inc. presented new preclinical data that demonstrate STAR-0215’s rapid and durable inhibition of plasma kallikrein in cynomolgus monkeys, supporting the potential for once every three month or longer dosing in humans.

Company Consolidates from Four Reporting Segments to Two, One Focusing on Biologics and the Other on Pharmaceuticals and Consumer Health.

Masimo (NASDAQ: MASI) today announced the findings of a two-part retrospective study published in Telemedicine and e-Health in which Dr. Hemali Patel and colleagues at the University of Colorado and UC Health (UCH) in Aurora, Colorado evaluated the impact of remote patient monitoring (RPM) of COVID-19 patients using Masimo SafetyNet® on hospital length of stay (LOS).

Perspectum Announces American Medical Association (AMA) Issues Two Unique Category III CPT ® Codes Priced Appropriately by the Centers for Medicare & Medicaid Services (CMS) for Noninvasive Biliary Anatomy Assessment With MRCP+.

Urovant Sciences and Pierre Fabre Médicament today announced they have entered into an exclusive license agreement for Pierre Fabre to register and commercialize vibegron for the treatment of Overactive Bladder (OAB).

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia.

Edward Hu to Replace Xiao Le as Non-Executive Director.

Dyadic International, Inc. today announced that its management and representatives will participate in the following two upcoming industry events in July 2022:

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022.